FoRx Therapeutics is a clinical-stage company that develops next-generation small molecule therapeutics targeting DNA Replication Stress pathways for anti-cancer therapy. The lead program is a highly potent and selective PARG inhibitor, FORX-428, which moved into clinical Phase 1 in H2 2025.
Products, services, technology
- Lead program: a highly potent and selective PARG inhibitor - FORX-428
- Preclinically, FORX-428 showed strong best-in-class potential, demonstrating greatly superior anti-tumor efficacy vs. competition.
- In the clinic, FORX-428 is being evaluated in patients with advanced solid tumors.
Cooperation possibilities
- Collaboration with pharma companies
- Out-Licensing
- M&A
- https://www.forxtherapeutics.com/
- +41782220082
- Send an email
- Tarig Bashir
